Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical donor multi-virus specific T-cell therapy for persistent viral infection after HSCT
jRCTa030190229Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2018
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of multi-virus-specific T cells in cytomegalovirus disease (CMV), Epstein-Barr virus infection, adenoviral infection and 2 more (3 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Grade 4 or higher non-hematologic toxicity and Grade III-IV acute graft-versus-host disease. Started Jun 2018; status: completed.
02
Drugs
multi-virus-specific T cells
03
Conditions
cytomegalovirus disease (CMV)Epstein-Barr virus infectionadenoviral infectionBK polyomavirus infectionhuman herpesvirus 6 infection
Beyond the preview
Go deeper on jRCTa030190229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa030190229.